NOVO.B.DK

425.75

-1.72%↓

COLO.B.DK

644.2

+1.51%↑

AMBUB.DK

105.2

+3.44%↑

NOVO.B.DK

425.75

-1.72%↓

COLO.B.DK

644.2

+1.51%↑

AMBUB.DK

105.2

+3.44%↑

NOVO.B.DK

425.75

-1.72%↓

COLO.B.DK

644.2

+1.51%↑

AMBUB.DK

105.2

+3.44%↑

NOVO.B.DK

425.75

-1.72%↓

COLO.B.DK

644.2

+1.51%↑

AMBUB.DK

105.2

+3.44%↑

NOVO.B.DK

425.75

-1.72%↓

COLO.B.DK

644.2

+1.51%↑

AMBUB.DK

105.2

+3.44%↑

Search

Genmab A-S

Închisă

1,322 2.12

Rezumat

Modificarea prețului

24h

Curent

Minim

1295

Maxim

1334

Indicatori cheie

By Trading Economics

Venit

-3.7B

195M

Vânzări

-5.7B

715M

P/E

Medie Sector

10.866

56.602

EPS

20.183

Marjă de profit

27.273

Angajați

2,638

EBITDA

-297M

1.8B

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

-1.49% downside

Dividende

By Dow Jones

Următoarele câștiguri

7 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-14B

82B

Deschiderea anterioară

1319.88

Închiderea anterioară

1322

Genmab A-S Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 mar. 2025, 15:16 UTC

Principalele dinamici ale pieței

Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option

10 dec. 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Comparație

Modificare preț

Genmab A-S Așteptări

Obiectiv de preț

By TipRanks

-1.49% jos

Prognoză pe 12 luni

Medie 2,493.35 DKK  -1.49%

Maxim 3,320 DKK

Minim 308.417 DKK

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGenmab A-S - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

7 ratings

3

Cumpărare

2

Păstrare

2

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.